

Single-Molecule Analyte Recognition with ClyA Nanopores Equipped with Internal Protein Adaptors


Misha Soskine,^{†,‡,§} Annemie Biesemans,^{‡,§} and Giovanni Maglia^{*,†,‡}

[†]Groningen Biomolecular Sciences & Biotechnology (GBB) Institute, University of Groningen, 9747 AG Groningen, The Netherlands

[‡]Department of Chemistry, University of Leuven, Leuven 3001, Belgium

S Supporting Information

ABSTRACT: Nanopores have been used to detect molecules, to sequence DNA, or to investigate chemical reactions at the single-molecule level. Because they approach the absolute limit of sensor miniaturization, nanopores are amenable to parallelization and could be used in single-cell measurements. Here we show that single enzymes can be functionally and reversibly trapped inside the confined space of a ClyA nanopore. Remarkably, the binding of ligands to the internalized proteins is mirrored by specific changes to the nanopore conductance. Conveniently, the manipulation of the charge of the protein allowed increasing of the residence time of the protein inside the nanopore. Nanopores with internalized protein adaptors can be used to study proteins in real time or can be incorporated into inexpensive portable devices for the detection of analytes with high selectivity.



INTRODUCTION

Over the past two decades, nanopore analysis has emerged as a promising analytical tool for single-molecule analysis.^{1–4} Nanopore technology allows the investigation of native molecules with high sampling bandwidth without the need for labeling, chemical modifications, or surface immobilization. Further, the ionic current output signal can be easily interfaced with miniaturized and portable electronic devices. For instance, arrays of nanopores integrated into a MinION sequencer have been recently used for the profiling of genomic DNA.^{5–7} Furthermore, biological nanopores have been reconstituted into bilayers formed on glass nanopipettes⁸ and on glass tips for scanning ion-conductance microscopy.⁹ Therefore, nanopore-functionalized nanopipettes that can detect and quantify metabolites are promising platforms for measurements in single cells.

Previous studies showed that small molecules binding to cyclodextrin¹⁰ and cyclic peptide¹¹ adaptors or cucurbituril carriers¹² could be detected by ionic current recordings using the α -hemolysin (α HL) nanopore. However, such guest adaptors and carriers do not bind selectively to host molecules, making the identification of analytes in a complex mixture of compounds a real challenge. By contrast, proteins have evolved to identify their ligands with high specificity in a sea of very similar chemical species. Therefore, nanopores equipped with protein adaptors would be ideal elements for integration into nanopore-based sensing devices for the analysis of complex biological samples. However, building such hybrid devices is challenging. Proteins are too large to be incorporated into the α HL and other biological nanopores^{13–15} and mostly translocate through solid-state nanopores too fast to be properly

sampled.¹⁶ Further, it is not known if the environment of the nanopore lumen is compatible with enzymatic functions, as experiments with solid-state nanopores revealed that proteins might be stretched by the electrical field¹⁷ and unfolded under applied potentials greater than +200 mV.¹⁸

Recently, we showed that folded proteins enter the lumen of type I ClyA-AS (C87A/L99Q/E103G/F166Y/I203V/C285S/K294R/H307Y), a dodecameric¹⁹ engineered version of ClyA from *Salmonella typhi* selected for its favorable properties in planar lipid bilayers.²⁰ Conveniently, ClyA also assembles into higher oligomeric forms (type II and type III ClyA)²⁰ that are large enough to accommodate, for example, protein–DNA complexes.²¹ Notably, we showed that electro-osmotic and electrophoretic forces allowed trapping proteins such as thrombin inside the ~ 240 nm³ cavity of type I ClyA nanopores for tens of minutes,^{20,22} suggesting that protein adaptors might be paired to ClyA nanopores without the use of covalent chemistry or other immobilization techniques. In this work, we report that the binding of analytes to two model proteins incorporated inside a ClyA nanopore is reflected by changes in the nanopore conductance, indicating that proteins immobilized inside the nanopore remain functional. Moreover, electrical readouts of nanopore-confined proteins will have applications in the fabrication of sensor arrays for the discovery of new therapeutics or the detection of biomarker analytes in biological samples.

Received: February 16, 2015

Published: April 14, 2015

RESULTS AND DISCUSSION

As a first model protein, we selected *Escherichia coli* AlkB demethylase ($M_w = 25$ kDa), a globular protein that is expected to pass the *cis* entry of ClyA but is too large to traverse the *trans* exit of the nanopore (Figure 1a,b). In complex with iron ions




Figure 1. Internalization of AlkB-Fe²⁺ into ClyA-AS. (a) Cartoon representation of *E. coli* AlkB (green) containing a metal ion (Co²⁺, red sphere) and binding to the cofactor (2-OG, blue spheres). The DNA binding site is depicted by an orange line. PDB ID 3KHB. (b) Representation of a single AlkB-Fe²⁺ enzyme (green) confined in a ClyA-AS nanopore (brown, shown as cross section) embedded in a planar lipid bilayer (light blue) under a negative applied potential. The dimensions of the pore consider the van der Waals radii of the atoms. (c) Top: Typical current blockades provoked by AlkB-Fe²⁺ molecules (~4 nM, *cis*) entering a ClyA-AS nanopore at -60 mV. The open pore current (I_0) is represented by a blue dashed line, while level 1 and level 2 are shown by red and green dashed lines, respectively. The red asterisks represent the restoration of I_0 upon the exiting of AlkB-Fe²⁺ from the pore. Bottom: Detail of a single AlkB-Fe²⁺ blockade, showing level 1 (red) and level 2 (green) current levels. The current traces were collected by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cutoff was digitally applied to the trace shown in (c), bottom. All recordings were carried out in 150 mM NaCl, 15 mM Tris-HCl, pH 8.0, at 28 °C, and the AlkB was added to the *cis* compartment.

(AlkB-Fe²⁺), AlkB co-oxidizes methylated DNA and its cofactor 2-oxoglutarate (2-OG), producing succinate (SUC), carbon dioxide, and formaldehyde.^{23,24} 2-Oxoglutarate is an important metabolite that influences aging and age-related diseases²⁵ and is a biomarker for nonalcoholic fatty liver disease,²⁶ heart failure,²⁷ and cardiorenal syndrome.²⁷ The level of succinate in urine is a biomarker for kidney damage.²⁸

Individual AlkB-Fe²⁺ molecules were studied using type I ClyA-AS (ClyA-AS hereafter). In 150 mM NaCl, 15 mM Tris-HCl and pH 8.0 ClyA-AS formed nanopores with a steady open pore conductance ($I_0 = -1.7 \pm 0.1$ nSi, average \pm SD, $N = 38$,

-60 mV, 28 °C) under a wide range of applied potentials. Here and hereafter, N indicates the number of independent single nanopore experiments, n_p the number of individual protein blockades, and n_l the total number of ligand binding events analyzed. The addition of AlkB-Fe²⁺ (~4 nM) to the *cis* side of ClyA-AS provoked current blockades (I_B), quoted here as residual currents calculated as a percentage of the open pore current ($I_{RES\%}$), due to the electro-osmotic confinement of AlkB-Fe²⁺ between the wider *cis* entrance and the narrower *trans* exit of the protein nanopore (Figure 1b).^{20,22} Conveniently, AlkB-Fe²⁺ remained trapped inside the nanopore for several minutes (Figure 1c). The signal induced by AlkB-Fe²⁺ fluctuated between two distinctive current levels, L1 ($I_{RES\%} = 52.6 \pm 2.0\%$, $n_p = 15$, $N = 7$) and L2 ($I_{RES\%} = 39.0 \pm 1.0\%$, $n_p = 15$, $N = 7$, Figure 1c), possibly due to two residence sites for the protein within the lumen of the ClyA nanopore.²²

At -60 mV, the addition to the *cis* reservoir of the cofactor (2-OG), an isosteric inhibitor (*N*-oxalylglycine, *N*-OG), or the processed cofactor (SUC) induced reversible current enhancements within the AlkB-Fe²⁺ blockades ($\Delta I_{RES\%} = +4.7 \pm 1.3\%$, $+4.9 \pm 1.0$ and $+4.6 \pm 1.3$, respectively, $n_p > 15$, $n_l > 75$, $N > 4$, Figure 2a and Supporting Information Figures S1 and S2 and Table S1) that showed a mean duration (τ_{off}) of 1.7 ± 0.5 s, 1.8 ± 0.4 s, and 61 ± 11 ms, respectively ($n_l > 4500$, $N > 8$, and $n_p > 80$). The current enhancements were also observed from the current level L2 (Figure S2). We hypothesized that such current events reflected the conformational changes occurring during the transition from the open conformation of the apoenzyme to the closed state of the ligand-bound form of AlkB-Fe²⁺ (Figure 2a).^{29,30} To confirm this hypothesis, we tested an AlkB mutant where the asparagine at position 120, which has been reported to be involved in the binding of 2-OG to AlkB,²⁹ was substituted by aspartate (N120D). The addition of 7.2 mM of 2-OG did not induce current transitions to the N120D-AlkB-Fe²⁺ blockades ($N = 4$, Figure 2a), suggesting that the affinity of this AlkB mutant for 2-OG is strongly reduced. As expected for a protein–ligand association process, the dissociation rate constants (k_{off} , Table S2), measured from the inverse of the dwell times of the ligand binding events ($1/\tau_{off}$), did not depend on the concentration of the ligand, while the frequencies of the ligand-induced events ($f = 1/\tau_{on}$) increased linearly with the concentration of the three ligands, from which slopes the association rate constants (k_{on}) could be calculated (Figure 2b and Table S2).

E. coli dihydrofolate reductase (DHFR, $M_w = 19$ kDa) was selected as a second model protein adaptor (Figure 3a,b). During the DHFR catalytic cycle, dihydrofolate is reduced to tetrahydrofolate and the cofactor NADPH is oxidized to NADP⁺. Tetrahydrofolate is a cofactor in many metabolic reactions, thus inhibitors of DHFR such as methotrexate (MTX) are antibiotic and anticancer agents. The ratio of the NADP⁺ and NADPH intracellular concentrations is used to monitor the oxidative stress in cells.³² We found that apo-DHFR, which is smaller than AlkB, dwelled inside ClyA-AS only for a few milliseconds. Upon the addition of MTX to the *cis* solution, the frequency and the dwell time of the protein blockades decreased, while the residual current increased (supporting results). The blockades were then abolished by the subsequent addition of NADPH to the same compartment (Figure S3). Since both the inhibitor and the cofactor are negatively charged, these results suggested that the additional negative charges increased the electrophoretic/electrostatic drag force, opposing DHFR entry and residence inside the




Figure 2. Binding of ligands to AlkB-Fe²⁺ confined inside ClyA-AS. (a) Typical ligand-induced blockades to individual AlkB-Fe²⁺ enzymes confined inside ClyA-AS at -60 mV. The ligand used is shown on the right of the trace. The bound level 1 current levels (L1_O, L1_N, L1_S) are represented by the blue dashed lines. The substrate concentration was 0.6 mM for 2-OG, 0.6 mM for N-OG, 2 mM for SUC binding to wild-type AlkB-Fe²⁺, and 7.2 mM for 2-OG binding to N120D-AlkB-Fe²⁺. (b) Left: Dissociation rate constants (k_{off}) as a function of the ligand concentration at -60 mV. Right: Event frequency ($1/\tau_{on}$) as a function of the ligand concentration at -60 mV. 2-OG is shown in yellow squares, SUC in black circles, and N-OG in red triangles. All current traces were collected by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cutoff was digitally applied to the current traces. All recordings were carried out in 150 mM NaCl, 15 mM Tris-HCl, pH 8.0 , at 28 °C, and the ligands were added to the *cis* compartment. Errors are given as standard deviations.

nanopore. In order to increase the residence time of the protein, we engineered DHFR by introducing a polypeptide tag containing four additional positive charges at the C-terminus of the protein (DHFR_{tag}, supporting results, Figure S4). In complex with MTX, the DHFR_{tag} added to the *cis* compart-




Figure 3. DHFR as a protein adaptor. (a) Cartoon representation of *E. coli* DHFR (cyan) with bound methotrexate (MTX, red spheres) and NADPH (blue spheres), PDB_ID 1RH3. (b) Representation of a single DHFR_{tag} enzyme (cyan) in complex with MTX (red) confined in a ClyA-AS nanopore (brown, shown as cross section) embedded in a planar lipid bilayer (light blue) under a negative applied potential. The positively charged polypeptide tag added at the C-terminus of DHFR is shown in blue. (c) Typical current blockades provoked by the capture of DHFR_{tag}:MTX complexes (20 nM DHFR_{tag}, 400 nM MTX, *cis*) by the ClyA-AS nanopore at -90 mV. The open pore current (I_O) is represented by a blue dashed line, while L1_M and L2_M are shown by red and green dashed lines, respectively. Red asterisks represent restoration of I_O upon the exiting of DHFR_{tag}:MTX from the pore. The current traces were collected in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5 , at 28 °C by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz.

ment, induced current blockades with a mean dwell time of 3.1 ± 1.4 s ($N = 5$, $n_p = 230$, Figure 3c) that was 3 orders of magnitude longer than DHFR_{tag} or DHFR:MTX blockades' mean dwell times. A possible explanation of this result is that, tuned by the additional positive charges, the binary DHFR_{tag}:MTX complex is at a potential minimum inside the nanopore where the electro-osmotic, electrophoretic, and electrostatic forces are balanced. The dissociation of MTX from the binary complex was slower than the residence time of the complex inside the nanopore and could not be observed by ionic current recordings. As shown before with apo-AlkB-Fe²⁺, DHFR_{tag}:MTX blockades showed a main current level L1 (L1_M, $I_{RES\%} = 74.7 \pm 0.5\%$, $n_p = 25$, $N = 5$) that rarely visited a second current level L2 (L2_M, $I_{RES\%} = 53.5 \pm 0.9\%$, $n_p = 25$, $N = 5$, Figure 3c).

At -90 mV, the addition of the oxidized cofactor NADP⁺ to the *trans* compartment of ClyA-AS produced reversible current enhancements to the DHFR_{tag}:MTX complex blockades formed in the *cis* solution (L1_{M:N+}, $\Delta I_{RES\%} = +2.3 \pm 0.5\%$, $n_p = 15$ blockades, $n_1 > 225$, $N = 3$; and $\tau_{M:N+} = 102 \pm 11$ ms, $n_1 = 19000$, $N = 9$, $n_p > 800$, Figure 4a and Supporting Information Table S3 and Figure S5). Association and dissociation rate constants could be measured from titration experiments (Figure 4b and Table S4). NADPH added to the *trans* compartment also induced additional current enhance-




Figure 4. Ligands binding to DHFR_{tag}. (a) Ligand-induced current enhancements to individual DHFR_{tag}:MTX blockades at -90 mV. NADP⁺ and NADPH are added to the *trans* compartment after addition of 20 nM DHFR_{tag} and 400 nM MTX to the *cis* compartment. From top to bottom: no ligand; 5.7 μM of NADP⁺; 0.7 μM of NADPH; 7.4 μM of NADP⁺ together with 0.7 μM of NADPH. Free and bound level 1 are shown by red and blue dashed lines, respectively. Red asterisks represent restoration of I_O upon the exit of DHFR_{tag}:MTX from the pore. On the right of the current traces is the schematic representation of the interaction of DHFR_{tag} (cyan) with MTX (red), NADP⁺ (yellow), or NADPH (blue). (b) Top: Dissociation rate constants (k_{off}) as a function of the NADP⁺ concentration added to the *trans* compartment at -90 mV. Bottom: Event frequency ($1/\tau_{\text{on}}$) as a function of the NADP⁺ concentration added to the *trans* compartment at -90 mV. Errors are shown as standard deviations. All current traces were collected by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cutoff was digitally applied to the traces shown in (a). All recordings were carried out in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5, at 28 °C.

ments to the binary complex blockades (Figure 4a). Remarkably, the current events induced by NADPH showed a slightly higher residual current (L1_{M:NH}, $\Delta I_{\text{RES}\%} = +2.7 \pm 0.7\%$, $n_p = 15$, $n_l = 15$, $N = 4$, Table S3) than the NADP⁺ blockades ($\Delta I_{\text{RES}\%} = +2.3 \pm 0.5\%$) and had a dwell time longer than the residence time of the ternary complex inside the nanopore (Figure 4a). As a consequence, despite the minute difference between NADPH and NADP⁺ (a hydride ion), the binding of the two ligands to DHFR_{tag}:MTX could be clearly differentiated (Figure 4a).

Although the bulk kinetic constants for the binding of NADP⁺ and NADPH to MTX:DHFR could not be retrieved from the literature, the equilibrium dissociation constant for the binding of 2-OG to AlkB-Mn²⁺ was recently measured by an intrinsic tryptophan fluorescence quenching assay ($K_D^{\text{bulk}} = 4.1 \pm 0.6 \times 10^{-6}$ M at 24 °C).³¹ By comparison, the equilibrium dissociation constant of 2-OG for AlkB-Fe²⁺ inside the nanopore measured from the ratio of the association and dissociation rate constants ($K_D^{\text{pore}} = k_{\text{off}}/k_{\text{on}}$) was about 2 orders of magnitude higher than the bulk value ($K_D^{\text{pore}} = 3.7 \pm 1.9 \times 10^{-4}$ M, -60 mV, 28 °C). This effect is likely to be

related to the confinement of AlkB-Fe²⁺ inside the nanopore and to the effect of the applied potential. ClyA nanopores have a negatively charged interior and are, therefore, cation selective.³³ Thus, under negative applied potentials (*trans*), the diffusion of the negatively charged ligands added to the *cis* solution through the nanopore is likely to be opposed. This is probably further accentuated by the unfavorable electrostatic interaction between the ligands and the wall of the nanopore lumen. This complication might be overcome by using nanopores with an internal charge with an opposite sign to that of the ligand to detect.

CONCLUSIONS

The results presented here indicate that the binding of analytes to proteins trapped inside ClyA can be monitored by specific changes in the nanopore conductance, suggesting that proteins confined inside nanopores remain functional. Proteins with suitable size and shape, such as AlkB, are sterically trapped between the wider *cis* entrance and the narrower *trans* exit of the pore. Smaller proteins, such as DHFR, that escape ClyA too quickly to allow the sampling of ligand binding kinetics can be

engineered with genetically encoded extensions to increase their residence time inside the nanopore. Our approach should also be applicable to larger protein adaptors, which could be internalized into larger nanopores such as higher oligomeric forms of ClyA,²⁰ Phi29,³⁴ pneumolysin,³⁵ or solid-state nanopores. Since most biologically active molecules have a protein target, nanopores with an internal protein adaptor are promising systems for integration in miniaturized low-cost electronic devices for medical, forensics, or environmental monitoring or for single-cell analysis.

■ ASSOCIATED CONTENT

📄 Supporting Information

Additional text, materials and methods, supporting tables, supporting figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*g.maglia@rug.nl

Author Contributions

§M.S. and A.B. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the European Research Council (European Commission's Seventh Framework Programme, Project No. 260884) for funding. A.B. is funded by a Ph.D. grant from the Agency for Innovation by Science and Technology (IWT) Flanders.

■ REFERENCES

- (1) Howorka, S.; Siwy, Z. *Chem. Soc. Rev.* **2009**, *38*, 2360.
- (2) Bayley, H. *Clin. Chem.* **2015**, *61*, 25.
- (3) Luchian, T.; Shin, S. H.; Bayley, H. *Angew. Chem., Int. Ed.* **2003**, *42*, 3766.
- (4) Bezrukov, S. M.; Vodyanoy, I.; Parsegian, V. A. *Nature* **1994**, *370*, 279.
- (5) Ashton, P. M.; Nair, S.; Dallman, T.; Rubino, S.; Rabsch, W.; Mwaigwisya, S.; Wain, J.; O'Grady, J. *Nat. Biotechnol.* **2015**, *33*, 296.
- (6) Mikheyev, A. S.; Tin, M. M. *Mol. Ecol. Resour.* **2014**, *14*, 1097.
- (7) Quick, J.; Quinlan, A. R.; Loman, N. J. *GigaScience* **2014**, *3*, 22.
- (8) White, R. J.; Ervin, E. N.; Yang, T.; Chen, X.; Daniel, S.; Cremer, P. S.; White, H. S. *J. Am. Chem. Soc.* **2007**, *129*, 11766.
- (9) Zhou, Y.; Bright, L. K.; Shi, W.; Aspinwall, C. A.; Baker, L. A. *Langmuir* **2014**, *30*, 15351.
- (10) Gu, L. Q.; Braha, O.; Conlan, S.; Cheley, S.; Bayley, H. *Nature* **1999**, *398*, 686.
- (11) Sanchez-Quesada, J.; Ghadiri, M. R.; Bayley, H.; Braha, O. *J. Am. Chem. Soc.* **2000**, *122*, 11757.
- (12) Braha, O.; Webb, J.; Gu, L. Q.; Kim, K.; Bayley, H. *ChemPhysChem* **2005**, *6*, 889.
- (13) Jung, Y.; Cheley, S.; Braha, O.; Bayley, H. *Biochemistry* **2005**, *44*, 8919.
- (14) Movileanu, L.; Howorka, S.; Braha, O.; Bayley, H. *Nat. Biotechnol.* **2000**, *18*, 1091.
- (15) Fahie, M.; Chisholm, C.; Chen, M. *ACS Nano* **2015**, *9*, 1089.
- (16) Plesa, C.; Kowalczyk, S. W.; Zinsmeister, R.; Grosberg, A. Y.; Rabin, Y.; Dekker, C. *Nano Lett.* **2013**, *13*, 658.
- (17) Oukhaled, A.; Cressiot, B.; Bacri, L.; Pastoriza-Gallego, M.; Betton, J. M.; Bourhis, E.; Jede, R.; Gierak, J.; Auvray, L.; Pelta, J. *ACS Nano* **2011**, *5*, 3628.
- (18) Freedman, K. J.; Haq, S. R.; Edel, J. B.; Jemth, P.; Kim, M. J. *Sci. Rep.* **2013**, *3*, 1638.
- (19) Mueller, M.; Gauschopf, U.; Maier, T.; Glockshuber, R.; Ban, N. *Nature* **2009**, *459*, 726.
- (20) Soskine, M.; Biesemans, A.; De Maeyer, M.; Maglia, G. *J. Am. Chem. Soc.* **2013**, *135*, 13456.
- (21) Van Meervelt, V.; Soskine, M.; Maglia, G. *ACS Nano* **2014**, *8*, 12826.
- (22) Soskine, M.; Biesemans, A.; Moeyaert, B.; Cheley, S.; Bayley, H.; Maglia, G. *Nano Lett.* **2012**, *12*, 4895.
- (23) Aravind, L.; Koonin, E. V. *Genome Biol.* **2001**, *2*, research0007.
- (24) Trewick, S. C.; Henshaw, T. F.; Hausinger, R. P.; Lindahl, T.; Sedgwick, B. *Nature* **2002**, *419*, 174.
- (25) Chin, R. M.; Fu, X.; Pai, M. Y.; Vergnes, L.; Hwang, H.; Deng, G.; Diep, S.; Lomenick, B.; Meli, V. S.; Monsalve, G. C.; Hu, E.; Whelan, S. A.; Wang, J. X.; Jung, G.; Solis, G. M.; Fazlollahi, F.; Kaweeteerawat, C.; Quach, A.; Nili, M.; Krall, A. S.; Godwin, H. A.; Chang, H. R.; Faull, K. F.; Guo, F.; Jiang, M.; Trauger, S. A.; Saghatelyan, A.; Braas, D.; Christofk, H. R.; Clarke, C. F.; Teitell, M. A.; Petrascheck, M.; Reue, K.; Jung, M. E.; Frand, A. R.; Huang, J. *Nature* **2014**, *510*, 397.
- (26) Rodriguez-Gallego, E.; Guirro, M.; Riera-Borrull, M.; Hernandez-Aguilera, A.; Marine-Casado, R.; Fernandez-Arroyo, S.; Beltran-Debon, R.; Sabench, F.; Hernandez, M.; Del Castillo, D.; Menendez, J. A.; Camps, J.; Ras, R.; Arola, L.; Joven, J. *Int. J. Obes.* **2014**, DOI: 10.1038/ijo.2014.53.
- (27) Nikolaidou, T.; Mamas, M.; Oceandy, D.; Neyses, L. *Heart* **2010**, *96*, e14.
- (28) Peti-Peterdi, J. Measurement of succinate in urine samples as a biomarker of kidney damage in diabetic subjects. U.S. Patent US8652771 B2, 2014.
- (29) Bleijlevens, B.; Shivarattan, T.; Flashman, E.; Yang, Y.; Simpson, P. J.; Koivisto, P.; Sedgwick, B.; Schofield, C. J.; Matthews, S. J. *EMBO Rep.* **2008**, *9*, 872.
- (30) Bleijlevens, B.; Shivarattan, T.; van den Boom, K. S.; de Haan, A.; van der Zwan, G.; Simpson, P. J.; Matthews, S. J. *Biochemistry* **2012**, *51*, 3334.
- (31) Ergel, B.; Gill, M. L.; Brown, L.; Yu, B.; Palmer, A. G., III; Hunt, J. F. *J. Biol. Chem.* **2014**, *289*, 29584.
- (32) Ogasawara, Y.; Funakoshi, M.; Ishii, K. *Biol. Pharm. Bull.* **2009**, *32*, 1819.
- (33) Ludwig, A.; Bauer, S.; Benz, R.; Bergmann, B.; Goebel, W. *Mol. Microbiol.* **1999**, *31*, 557.
- (34) Wendell, D.; Jing, P.; Geng, J.; Subramaniam, V.; Lee, T. J.; Montemagno, C.; Guo, P. *Nat. Nanotechnol.* **2009**, *4*, 765.
- (35) Gilbert, R. J.; Jimenez, J. L.; Chen, S.; Tickle, I. J.; Rossjohn, J.; Parker, M.; Andrew, P. W.; Saibil, H. R. *Cell* **1999**, *97*, 647.